Department of Surgery, Division of HPB and Transplant Surgery, Erasmus MC University Medical Centre, Rotterdam, the Netherlands.
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, the Netherlands.
J Hepatol. 2018 Apr;68(4):707-714. doi: 10.1016/j.jhep.2017.11.030. Epub 2017 Dec 6.
BACKGROUND & AIMS: Frail patients with low model for end-stage liver disease (MELD) scores may be under-prioritised. Low skeletal muscle mass, namely sarcopenia, has been identified as a risk factor for waiting list mortality. A recent study proposed incorporating sarcopenia in the MELD score (MELD-Sarcopenia score). We aimed to investigate the association between sarcopenia and waiting list mortality, and to validate the MELD-Sarcopenia score (i.e. MELD + 10.35 * Sarcopenia).
We identified consecutive patients with cirrhosis listed for liver transplantation in the Eurotransplant registry between 2007-2014 and measured skeletal muscle mass on computed tomography. A competing risk analysis was used to compare survival of patients with and without sarcopenia, and concordance (c) indices were calculated to assess performance of the MELD and MELD-Sarcopenia score. We created a nomogram of the best predictive model.
We included 585 patients with a median MELD score of 14 (interquartile range 9-19), of which 254 (43.4%) were identified as having sarcopenia. Median waiting list survival was shorter in patients with sarcopenia than those without (p <0.001). This effect was even more pronounced in patients with MELD ≤15. The discriminative performance of the MELD-Sarcopenia score (c-index 0.820) for three-month mortality was lower than MELD score alone (c-index 0.839). Apart from sarcopenia and MELD score, other predictive variables were occurrence of hepatic encephalopathy before listing and recipient age. A model including all these variables yielded a c-index of 0.851.
Sarcopenia was associated with waiting list mortality in liver transplant candidates with cirrhosis, particularly in patients with lower MELD scores. The MELD-Sarcopenia score was successfully validated in this cohort. However, incorporating sarcopenia in the MELD score had limited added value in predicting waiting list mortality.
In this study among patients with liver cirrhosis listed for liver transplantation, low skeletal muscle mass was associated with mortality on the waiting list, particularly in patients who were listed with low priority based on a low MELD score. However, adding these measurements to the currently used system for donor and organ allocation showed no added value.
低终末期肝病模型评分(MELD)的虚弱患者可能被低估。低骨骼肌量,即肌少症,已被确定为等待名单死亡率的一个危险因素。最近的一项研究提出将肌少症纳入 MELD 评分(MELD-Sarcopenia 评分)。我们旨在研究肌少症与等待名单死亡率之间的关系,并验证 MELD-Sarcopenia 评分(即 MELD+10.35*肌少症)。
我们在 2007 年至 2014 年间在 Eurotransplant 注册中心连续识别出因肝硬化而接受肝移植的患者,并在计算机断层扫描上测量骨骼肌量。使用竞争风险分析比较有和无肌少症患者的生存情况,并计算一致性(c)指数以评估 MELD 和 MELD-Sarcopenia 评分的性能。我们创建了最佳预测模型的列线图。
我们纳入了 585 名中位 MELD 评分为 14(四分位距 9-19)的患者,其中 254 名(43.4%)被确定为肌少症患者。有肌少症的患者等待名单生存时间短于无肌少症的患者(p<0.001)。在 MELD≤15 的患者中,这种影响更为明显。MELD-Sarcopenia 评分(c 指数 0.820)对三个月死亡率的判别性能低于单独的 MELD 评分(c 指数 0.839)。除肌少症和 MELD 评分外,其他预测变量包括在列入名单前发生肝性脑病和受者年龄。包括所有这些变量的模型产生的 c 指数为 0.851。
肌少症与肝硬化肝移植候选者的等待名单死亡率相关,特别是在 MELD 评分较低的患者中。MELD-Sarcopenia 评分在该队列中得到了成功验证。然而,将肌少症纳入 MELD 评分在预测等待名单死亡率方面的附加值有限。
在这项对因肝硬化而接受肝移植的患者进行的研究中,低骨骼肌量与等待名单上的死亡率相关,特别是在基于低 MELD 评分而被列为低优先级的患者中。然而,将这些测量值添加到目前用于供体和器官分配的系统中并没有增加价值。